INTRODUCTION
Pos raumatic stress disorder (PTSD) can develop in individuals exposed to traumatic events. Regarding the violent nature of war, combat and its related experiences are an established cause of this disorder. [1] The lifetime prevalence of PTSD is approximately 7.8% in the general population, 10.4% in women, and 5% in men. [1, 2] The prevalence among Iran Earth Force staff has been estimated 9.14%. [3] At least one-third of PTSD suff erers remain persistently symptomatic. [1, 4] More than 50% of Iranian veterans in Iraq war suff er symptoms of chronic PTSD. [5] The symptoms may have a profound infl uence on patients, families, healthcare system and the society. The burden is felt not only by suff erers and their families but also by co-workers, employers, health care providers and wider society. [6] PTSD is resistant to many pharmacological therapies. [4] Among all symptom clusters, avoidance and numbing are symptoms associated with chronicity of the illness, and with decreased life quality; [7, 8] notably, most therapies have li le eff ect on this cluster of symptoms. [9, 10] were given written and oral information about the study process and drug profi le; also, wri en informed consents were obtained. This trial has been registered with Iranian Registry of clinical Trials (Registration Number: IRCT2013121015741N1).
Study design and participants
This was an 11-week, double-blind, randomized, placebocontrolled, clinical trial, conducted in out-patient psychiatry clinics affi liated to the IUMS in Isfahan, Iran [ Figure 1 ]. The studied population was selected randomly among outpatients with chronic combat-related PTSD (based on DSM-IV-TR criteria for chronic PTSD), who were males over 18 and <65 years of age, and whose records were registered in the university affi liated psychiatric outpatient clinics in Isfahan. Patient sampling, data collection and analysis, were conducted form late 2012 to mid-2013.
A total of 319 patients were screened for eligibility. Psychiatric and general medical records were reviewed; patients were excluded if, according to their records, they had criteria of another DSM-IV-TR diagnosis, or comorbid psychiatric condition including depression, suicidal or homicidal risk, or substance dependence, a serious medical problem, such as history of severe allergy or drug reaction, blood cell dyscrasia, cardiac infarction or arrhythmia, seizure, uncontrolled migraine, head trauma, and severe renal or hepatic insuffi ciency. [30] [31] [32] Patients were also required to be on a stable, adequate psychiatric treatment regimen for the past 3 months, otherwise they were excluded. Based on aforementioned exclusion criteria, among 319 screened patients, 209 were excluded in this step, and 18 refused to participate [ Figure 2 ]. Screening and enrolment were accomplished by two psychiatrists, one senior resident of psychiatry and an expert psychologist. Sample volume was calculated to be 50 (Z α = 1.96, Z β = 0.84). However, having predicted the sample loss, 76 subjects (~n + 15% n) were randomly selected among the eligible patients.
Procedure and assessment
The patients were interviewed based on structured, DSM-IV-TR criteria by a board certifi ed a ending psychiatrist to confi rm the diagnosis of PTSD and to rule out other diagnoses or comorbidities. [4, 31] Age, marital status, occupation, years of education, years of the disorder duration, psychiatric comorbidities, previous and current psychopharmacologic and psychotherapeutic treatments, concurrent medical illnesses and medications were registered, and clinician administered PTSD scale (CAPS) was fi lled as baseline. General and neurological physical examination, electrocardiogram, blood chemistry, hematology, thyroid, liver and renal function tests were performed, and patients who had abnormal results were excluded. Information about the study process and the drug profi le was provided for patients, and wri en consents were obtained. To provide a base line and to ensure patients' compliance and stability, all patients entered a 1-week run-in period, during which they received placebo. The previously stable therapeutic regimens were continued during the study course. [4, 31] Patients were excluded if they had poor treatment adherence during the run-in period [ Figures 1 and 2] .
Primarily, 38 patients were randomly allocated to each group, using random-numbers table. However, the number decreased during the process due to drop-out [ Figure 2 ]. The expert epidemiologist, who generated random allocation scheme, was not involved in other steps of the study. Furthermore, the two expert psychologists that implemented the random allocation and assignment did not participate in other parts of the trial. Allocation was concealed by means of sequentially coded sealed envelopes. During the next 4-week, one group received an add-on treatment of 25 mg of DCS (Eli-Lilly, Indianapolis, Indiana) twice daily, [4] while the other received placebo. [4, 24] An a ending professor of psychiatry administered the medication in the university clinic. As all patients were already on various psychopharmacologic treatments, either DCS or placebo was added to the stable previous regimen. At the end of this period (5 th week), both groups were assessed through clinical interview, CAPS and drug side eff ect questionnaire by a senior resident of psychiatry. Physical exam, laboratory tests and electrocardiogram were performed. Both groups entered a 2-week washout period. [4] Following washout, the two groups received cross-over treatments for 4-week [ Figures 1 and 2 ]. Psychiatric and general medical assessments were re-obtained at the end of the 11 th week through clinical interview, CAPS, side eff ect questionnaire and paraclinical tests by the same senior resident. Patients, the psychiatrists who performed the interviews or administered medication, and a resident who fi lled the questionnaires and assessed clinical and paraclinical work-ups were blinded to the patients' group assignment [ Figure 2 ].
The Persian version of CAPS (test-retest reliability = 0.86, Cronbach's α = 0.92) was used to evaluate patients' PTSD state and to assess intervention outcomes. [33] It is widely used for diagnostic purposes, and for tracking fi ne changes in symptom frequency or intensity over time or as a treatment outcome. [34, 35] Since it is the most valid [34, 35] and a highly reliable assessment tool for PTSD, it has become a standard criterion measure in this fi eld. [33] [34] [35] CAPS is a structured interview corresponding to DSM-IV criteria, addressing all symptom clusters separately. B, C and D symptom clusters are rated for both frequency and intensity (including the impact of symptoms on patient's function). Frequency scores range from 0 to 4 (scale 0 = none of the time, 4 = most or all of the time), and the overall frequency score is calculated by summing frequency scores of all symptom. Likewise, intensity scores embrace 0-4 (scale 0 = none, 4 = extreme). Furthermore, intensity scores are summed to provide the overall intensity rating. Frequency and intensity scores are calculated for all symptom questions and/or for the three symptom clusters. Alternative scoring systems have also been suggested. Other questions assess criteria A, E and F. Besides, additional items inquire about guilt and dissociation. The whole interview consists of six clusters, including 60 questions. The overall score may range from 0 to 148. The present study focuses on criterion C (avoidance and numbing) which assesses seven symptoms through 21 questions; seven questions address the presence/absence of symptoms by means of yes/no answers, fi nally representing as the number of symptoms. Another seven questions assess the frequency of symptoms (scale 0 = none of the time, 4 = most or all of the time). And the other seven inquire how intensive the symptoms are and how they aff ect the patient's life and function. [33] [34] [35] Both frequency and intensity scores ranged from 0 to 28. CAPS was fi rst fi lled for each participant as a base line, and then at the end of each intervention period.
The primary outcomes were the overall number of avoidance and numbing symptoms, symptom frequency, and symptom intensity, which were measured separately. Secondary outcomes were tolerability and safety of DCS assessed through the side eff ect questionnaire, clinical and paraclinical evaluation. Outcomes were measured at the end of each intervention period, that is, at the end of the 5 th and 11 th week of the trial.
Statistical analysis
The study was designed as cross-over; within-group analysis has been performed, and main eff ect has been measured. 
RESULTS
A total of 319 patients were screened, and 76 patients entered the study; 38 patients were randomized to either group. Fourteen patients dropped out during the study process. Finally, 31 patients entered the analysis in each group [ Figure 2 ]. N o t a b l y, a l l p a t i e n t s h a d a l r e a d y b e e n o n psychopharmacologic treatments, including various combinations of antidepressants, antipsychotics, mood stabilizers, sedative-hypnotics, and, etc. Among all participants, 7 patients followed marital therapy, two participated family therapy, and fi ve received individual cognitive therapy.
Analysis of CAPS numbing and avoidance scores in the run-in period reveals that both groups had a similar profi le except for the frequency of restricted range of aff ect (t 73 = 2.01, P = 0.047) and intensity of decreased interest or participation in activities and related interference and impact on function (t 73 = 2.30, P = 0.024).
The mean number of avoidance and numbing symptoms for DCS and placebo were 2.7 ± 2.3 and 5.2 ± 1.9 respectively at the end of the fi rst-intervention period (5 th week), and 3.7 ± 1.9 and 5.1 ± 1.7 respectively at the end of the second period (11 th week). The mean diff erence of the total numbers of avoidance and numbing symptoms between DCS and placebo was found to be 1.13 ± 0.64, and, therefore, the main effect was nonsignificant (t 60 = 1.76, P = 0.083). Carry-over and period eff ects were not signifi cant either [ Table 1 ].
There were no significant differences between DCS and placebo regarding overall avoidance and numbing symptom frequency (t 60 = 1.14, P = 0.259) [ Table 2 ].
Signifi cant reduction of overall symptom intensity and impact on function was observed in DCS treatment (mean diff erence [standard error] = −4.22 [1.53], P = 0.008). As significant carry-over effect was detected, implying inadequate washout period, the analysis has only been confi ned to the fi rst-intervention period [ Table 3 ].
No clinically signifi cant adverse eff ect was observed with DCS; and none of the patients dropped out because of side eff ects. Clinical examination and paraclinical tests including electrocardiography, blood cell count and chemistry, thyroid, liver and renal function tests did not reveal considerable changes. Although nonsignifi cant, the reported side eff ects were mild head (χ 
DISCUSSION
Since war is characterized by extreme violence, combat veterans are at high risk of developing PTSD. [1, 4, 36] The disorder tends to follow a chronic course in roughly one third of patients. [1, [3] [4] [5] The burden of chronicity of PTSD is prominent in terms of individual health and function, family life, work-place behaviors, employment issues and health care services. [6] [7] [8] Despite many available pharmacologic therapies, the disorder is treatment resistant. [4, 36] Notably, among many symptoms of PTSD, numbing and avoidance are closely associated with chronicity and decreased life quality; besides, they show li le response to current treatments. [7, 8] This cross-over trial is among the few studies focusing on clinical effi cacy of add-on DCS in the treatment of avoidance and numbing in chronic PTSD. [4, 24, 25] Our fi nding suggests that adjunctive DCS (50 mg/day) can help ameliorate the intensity of emotional numbing and avoidance, and improve patients' function by modifying the impact of symptoms on their lives. Yet it failed to diminish the frequency and the number of symptoms. It is noteworthy that the aforementioned dosage of DCS turned out to be safe and well-tolerated.
From a neurochemical point of view, an aspect of PTSD is disability in extinction of traumatic injury.
[11] Stressors are registered and remembered when they activate NMDA receptor which consequently produces a long-term memory. [4] On the other hand, symptoms like diminished interest, restricted affect, detachment, and social withdrawal, very much like negative symptoms of schizophrenia, have been suggested to be associated with dysfunction or dysregulation of NMDA receptor. [4, 23] As DCS plays a partial agonist role at glycine regulatory site on NMDA synaptic receptor complex, it has positive eff ects on new learning, memory consolidation and retrieval processes in rodent studies. [4, 24] Previous studies on the effi cacy of DCS in treatment of PTSD have demonstrated disconsonant results. In a controlled trial by de Kleine et al., augmentation of exposure therapy with DCS did not enhance the overall treatment outcome; but it yielded higher symptom reduction in more severe PTSD cases. [26] Moreover, controlled trial by Litz et al. indicated that imaginal exposure plus DCS in combat-related PTSD leads to increased PTSD symptoms. [27] On the other hand, a recent pilot-controlled trial by Difede et al. showed greater remission rate of PTSD symptoms. [25] Furthermore, Heresco-Levy et al. used DCS for treatment of PTSD in a pilot-controlled study; DCS treatment was not only associated with a signifi cant decrease in total PTSD scores but also with a noticeable reduction in numbing, avoidance and anxiety; yet similar improvements were also found during placebo treatment. [4] The inconsistency of results of diff erent studies can be viewed in terms of methodology; as in some studies, subjects were solely males, while in others patients were majorly females. Furthermore, trials have addressed different trauma types; as some have focused on sexual assaults while others have studied combat-related PTSD. [24] Our present study suggests that DCS can function as an adjunctive therapy to reduce the intensity of numbing and avoidance in chronic PTSD, and can help improve patients' function in this regard.
The fact that subjects of our sample were exclusively males, exposed to combat trauma, may interfere with generalizablity. Moreover, regarding the signifi cant carryover eff ect in the assessment of intensity and function impairment, a 2-week washout appears to be insuffi cient. Besides, a decreasing, but nonsignificant trend in the number of symptoms during DCS treatment suggests that a larger sample volume may lead to more obvious results. Patients were either receiving disability payment or litigating to receive support pension; therefore, treatment results might have been infl uenced.
